BioTelemetry (BEAT) Upgraded by BidaskClub to “Buy”
BioTelemetry (NASDAQ:BEAT) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.
A number of other equities analysts have also recently issued reports on BEAT. Dougherty & Co reiterated a “buy” rating and issued a $41.00 price objective (up from $40.00) on shares of BioTelemetry in a report on Friday, February 23rd. Zacks Investment Research lowered BioTelemetry from a “hold” rating to a “sell” rating in a research note on Thursday, February 8th. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. BioTelemetry presently has an average rating of “Buy” and a consensus target price of $43.00.
BioTelemetry (NASDAQ:BEAT) opened at $34.10 on Friday. BioTelemetry has a fifty-two week low of $23.30 and a fifty-two week high of $39.20. The company has a quick ratio of 1.66, a current ratio of 1.77 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $1,109.31, a PE ratio of -69.59, a PEG ratio of 1.68 and a beta of 0.75.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP lifted its stake in shares of BioTelemetry by 577.1% in the 3rd quarter. Quantbot Technologies LP now owns 9,087 shares of the medical research company’s stock valued at $299,000 after acquiring an additional 7,745 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in shares of BioTelemetry by 81.4% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 15,239 shares of the medical research company’s stock valued at $503,000 after acquiring an additional 6,838 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of BioTelemetry in the 3rd quarter valued at about $337,000. Summit Creek Advisors LLC lifted its stake in shares of BioTelemetry by 11.9% in the 4th quarter. Summit Creek Advisors LLC now owns 380,062 shares of the medical research company’s stock valued at $11,364,000 after acquiring an additional 40,366 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of BioTelemetry by 6.5% in the 3rd quarter. Legal & General Group Plc now owns 55,503 shares of the medical research company’s stock valued at $1,831,000 after acquiring an additional 3,385 shares during the last quarter. 87.49% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “BioTelemetry (BEAT) Upgraded by BidaskClub to “Buy”” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2018/03/11/biotelemetry-beat-upgraded-by-bidaskclub-to-buy.html.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.